EB病毒特异性细胞毒T淋巴细胞治疗复发难治性NK/T细胞淋巴瘤(鼻型)1例报告并文献复习  

EPSTEIN-BARR VIRUS-SPECIFIC CYTOTOXIC T CELLS IN TREATMENT OF RECURRENT REFRACTORY NATURAL KILLER/T-CELL LYMPHOMA (NASAL TYPE): A CASE REPORT AND LITERATURE REVIEW

作　　者：张耀文 史春雷[2] 费海荣 王玲[2] ZHANG Yaowen;SHI Chunlei;FEI Hairong;WANG Ling(Medical College of Qingdao University,Qingdao 266071,China)

机构地区：[1]青岛大学医学部,山东青岛266071 [2]青岛大学第二临床医学院(青岛市中心医院)血液科

出　　处：《青岛大学学报（医学版）》2021年第5期777-779,共3页Journal of Qingdao University(Medical Sciences)

基　　金：山东省医药卫生科技发展计划项目(2015WS0315)。

摘　　要：目的探讨EB病毒特异性细胞毒T淋巴细胞(EBV-CTL)治疗复发难治性NK/T细胞淋巴瘤(鼻型)的可行性。方法报告1例女性结外NK/T细胞淋巴瘤(鼻型)病人,病人给予培门冬酶+GDP方案化疗以及2 Gy(12次)局部放疗,病情进展,免疫组化检测EBER阳性,再次给予3疗程EBV-CTL治疗。结果病人采用EBV-CTL治疗后4个月达到完全缓解,而且细胞治疗过程中无明显不良反应,病人耐受性好。结论 EBV-CTL可以作为治疗复发难治性NK/T细胞淋巴瘤的一个选择。Objective To investigate the feasibility of Epstein-Barr virus-specific cytotoxic T cells(EBV-CTL) in the treatment of recurrent refractory natural killer/T-cell lymphoma(nasal type). Methods This article reported a female patient with extranodal natural killer/T-cell lymphoma. The patient was given chemotherapy with pegaspargase-GDP regimen and local radiotherapy at a dose of 2 Gy for 12 times. Disease progression was observed and immunochemistry showed positive EBER. The patient was given another three courses of EBV-CTL therapy. Results The patient achieved complete remission at 4 months after EBV-CTL therapy. No obvious adverse reactions were observed during the treatment, and the patient had good tolerance. Conclusion EBV-CTL therapy can be used as a choice for the treatment of recurrent refractory natural killer/T-cell lymphoma.

关 键 词：淋巴瘤 结外NK-T细胞 造血干细胞移植 免疫疗法 病例报告 

分 类 号：R733.4[医药卫生—肿瘤] R457[医药卫生—临床医学]